Assessing the role of IL-35 in colorectal cancer progression and prognosis

International Journal of Clinical and Experimental Pathology

Bin Kong¹  Long He¹  Wan-Dang Wang¹  Bin-Hua Wu¹  Tian-Yu Li¹  Wen-Yu Xiang¹  Jun-Fa Xu¹  Jun-Ai Zhang¹  Shu Zhang¹  Zhi Zhang¹  Yan-Fang Liang¹  Jin-Cheng Zeng¹  Jing-Jing Bao¹  Zhi-Yong Wang¹  Xiao-Dong Chen¹  Cong-Yi Wang¹  Hong-Mei Wang¹ 

关键词: Interleukin-35;    colorectal cancer;    regulatory T cell;    EBI3;    IL-12p35;   

DOI  :  

学科分类：生理学与病理学

来源: e-Century Publishing Corporation

【 摘 要 】

Despite the recent realization of Interleukin (IL)-35 in tumorigenesis, its exact impact on colorectal cancer (CRC) progression and prognosis, however, is yet to be elucidated clearly. We thus in the present report conducted comparative analysis of IL-35 levels between CRC patients and matched control subjects. IL-35 is highly expressed in all CRC tissues, which can be detected in vast majority of colorectal cancer cells. IL-35 levels in CRC lysates and serum samples are highly correlated to the severity of malignancy and the clinical stage of tumor. Particularly, a significant reduction for serum IL-35 was noted in patients after surgical resection, indicating that IL-35 promotes CRC progression associated with poor prognosis. Mechanistic study demonstrated a significant correlation between serum IL-35 levels and the number of peripheral regulatory T (Treg) cells in CRC patients, suggesting that IL-35 implicates in CRC pathogenesis probably by inducing Treg cells, while cancer cell-derived IL-35 may also recruit Treg cells into the tumor microenvironment in favor of tumor growth. Together, our data support that IL-35 could be a valuable biomarker for assessing CRC progression and prognosis in clinical settings.

【 授权许可】

Unknown